MNOV - MediciNova Inc Stock Price, Fair Value and News

1.31USD-0.01 (-0.76%)Market Closed

Market Summary

USD1.31-0.01

Market Closed

-0.76%

MNOV Stock Price

View Fullscreen

MNOV RSI Chart

MNOV Valuation

Market Cap

64.3M

Price/Earnings (Trailing)

-7.5

Price/Sales (Trailing)

35.02

EV/EBITDA

-1.55

Price/Free Cashflow

-8.62

MNOV Price/Sales (Trailing)

MNOV Profitability

EBT Margin

-467.03%

Return on Equity

-13.74%

Return on Assets

-12.93%

Free Cashflow Yield

-11.6%

MNOV Fundamentals

MNOV Revenue

Revenue (TTM)

1.8M

Rev. Growth (Yr)

2.1%

Rev. Growth (Qtr)

-0.38%

MNOV Earnings

Earnings (TTM)

-8.6M

Earnings Growth (Yr)

31.4%

Earnings Growth (Qtr)

-184.76%

Breaking Down MNOV Revenue

Last 7 days

-5.8%

Last 30 days

-10.9%

Last 90 days

-10.9%

Trailing 12 Months

-38.2%

How does MNOV drawdown profile look like?

MNOV Financial Health

Current Ratio

15.61

MNOV Investor Care

Diluted EPS (TTM)

-0.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.3M	1.6M	1.8M	1.8M
2022	3.2M	2.4M	1.6M	809.7K
2021	7.4M	8.7M	9.9M	4.0M
2020	6.6M	7.0M	6.6M	6.2M
2019	1.7M	1.7M	1.8M	6.5M
2018	7.8M	5.7M	3.6M	1.5M
2017	2.6M	5.0M	7.5M	9.9M
2016	495.5K	383.5K	271.5K	159.5K
2015	2.9M	2.1M	1.4M	607.5K
2014	5.4M	4.8M	4.3M	3.7M
2013	3.4M	0	0	6.0M
2012	0	0	0	802.6K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of MediciNova Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 28, 2022	nagao hideki	sold	-15,196	2.25	-6,754	-
Nov 22, 2022	nagao hideki	sold	-464	2.13	-218	-
Nov 21, 2022	nagao hideki	sold	-11,695	2.18	-5,365	-
Nov 17, 2022	nagao hideki	sold	-673	2.18	-309	-
Aug 23, 2021	matsuda kazuko	acquired	138,000	2.3	60,000	chief medical officer
Jul 09, 2021	iwaki yuichi	acquired	100,541	2.54	39,583	president and ceo
Jun 24, 2021	matsuda kazuko	acquired	256,622	2.49623	102,804	chief medical officer
May 19, 2021	obrien geoffrey	acquired	109,122	2.5191	43,318	vice president
Mar 11, 2021	nagao hideki	sold	-17,419	7.4	-2,354	-
Feb 25, 2021	iwaki yuichi	acquired	212,175	2.46	86,250	president and ceo

Which funds bought or sold MNOV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	added	102	-	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-19.79	-40,392	139,449	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-3,000	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.05	-354,203	934,999	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	32,832	32,832	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	-12,000	32,000	-%
Feb 15, 2024	BARCLAYS PLC	reduced	-12.04	-80,000	137,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	21,518	21,518	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-85,636	217,721	-%
Feb 14, 2024	Royal Bank of Canada	new	-	1,000	1,000	-%

Are Funds Buying or Selling MNOV?

Are funds buying MNOV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MNOV

No. of Funds

Unveiling MediciNova Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jul 12, 2022	3d investment partners pte. ltd.	11.2%	5,502,047	SC 13D/A
Jul 12, 2021	blackrock inc.	2.3%	1,127,922	SC 13G/A
Jan 29, 2021	blackrock inc.	7.4%	3,313,971	SC 13G/A
Jan 21, 2021	3d investment partners pte. ltd.	11.3%	5,502,047	SC 13D
Feb 05, 2020	blackrock inc.	6.5%	2,835,590	SC 13G/A

Recent SEC filings of MediciNova Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 01, 2024	8-K	Current Report
Feb 15, 2024	10-K	Annual Report
Jan 19, 2024	S-8 POS	Employee Benefits Plan
Jan 19, 2024	S-8 POS	Employee Benefits Plan
Jan 19, 2024	S-8 POS	Employee Benefits Plan
Jan 19, 2024	S-8 POS	Employee Benefits Plan

Peers (Alternatives to MediciNova Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

MediciNova Inc News

Latest updates

MediciNova Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-0.4%	436,265	437,934	451,420	509,046	427,304	253,755	91,275	45,638	-	37,500	-	4,000,000	5,863,904	3,313,194	762,483	412,692	5,569,048	288,643	307,574	304,245	865,092
Operating Expenses	16.0%	2,490,104	2,146,888	3,300,030	2,963,243	3,231,235	3,897,467	4,089,935	3,410,012	2,102,831	3,639,439	4,309,513	4,201,529	3,013,442	3,730,016	4,510,366	2,924,499	2,224,132	2,645,565	4,182,021	4,979,359	492,000
S&GA Expenses	-37.9%	839,326	1,352,182	1,564,295	1,486,567	1,218,611	1,443,264	1,524,966	1,298,016	325,819	1,550,821	1,782,390	2,056,255	1,216,265	1,492,139	2,311,330	1,673,754	395,295	1,494,750	2,716,509	3,345,481	277,770
EBITDA Margin	-Infinity%	-4.66	-	-8.56	-10.96	-17.35	-6.25	-4.17	-3.13	-2.50	-1.40	-1.60	-1.86	-2.24	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	343
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-206,233
EBT Margin	-Infinity%	-4.67	-	-8.57	-10.98	-17.37	-6.27	-4.18	-3.14	-2.51	-1.40	-1.60	-1.87	-2.24	-	-	-	-	-	-	-	-
Net Income	-184.8%	-2,059,085	-723,107	-2,871,820	-2,917,504	-3,001,484	-3,652,184	-4,028,998	-3,386,417	-2,083,145	-3,579,167	-4,284,141	-187,799	-2,985,289	-3,703,820	-4,451,229	-2,713,559	-1,984,088	-2,378,504	-3,881,876	-4,697,190	-208,000
Net Income Margin	10.3%	-4.67	-5.21	-7.58	-10.61	-17.38	-8.13	-5.40	-4.13	-2.51	-1.11	-1.29	-1.53	-	-	-	-	-	-	-	-	-
Free Cashflow	63.7%	-499,038	-1,374,293	-2,383,016	-3,177,413	-4,007,044	-2,720,151	-2,455,968	-3,728,400	-3,638,966	-3,018,561	1,094,238	-3,886,650	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-2.7%	66.00	68.00	69.00	71.00	74.00	78.00	81.00	84.00	87.00	92.00	94.00	96.00	75.00	77.00	76.00	77.00	79.00	78.00	77.00	79.00	77.00
Current Assets	-3.4%	51.00	53.00	54.00	56.00	59.00	53.00	66.00	69.00	72.00	76.00	79.00	81.00	61.00	63.00	61.00	62.00	64.00	63.00	62.00	64.00	63.00
Cash Equivalents	-1.0%	51.00	52.00	53.00	55.00	19.00	53.00	65.00	68.00	71.00	75.00	78.00	76.00	60.00	62.00	60.00	61.00	64.00	63.00	62.00	63.00	62.00
Net PPE	-10.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Liabilities	12.2%	4.00	3.00	4.00	3.00	4.00	5.00	5.00	4.00	4.00	5.00	4.00	4.00	4.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00
Current Liabilities	17.0%	3.00	3.00	3.00	3.00	3.00	5.00	4.00	3.00	3.00	4.00	2.00	2.00	2.00	2.00	3.00	2.00	2.00	2.00	2.00	1.00	2.00
Shareholder's Equity	-3.5%	62.00	65.00	65.00	68.00	70.00	73.00	77.00	80.00	84.00	86.00	89.00	92.00	71.00	74.00	71.00	73.00	75.00	74.00	73.00	75.00	73.00
Retained Earnings	-0.5%	-415	-413	-412	-410	-407	-404	-400	-396	-393	-390	-387	-383	-382	-379	-376	-371	-369	-367	-364	-360	-356
Additional Paid-In Capital	0.0%	478	478	478	478	477	477	477	477	477	478	477	476	454	454	447	445	444	441	438	436	429
Shares Outstanding	0%	49.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	48.00	48.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	109	-	-	-	118	-	-	-	197	-	-	-	227	-	-	-	393	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	63.6%	-499	-1,371	-2,383	-3,177	-4,007	-2,720	-2,455	-3,728	-3,638	-3,015	1,127	-3,853	-1,949	-3,908	-2,090	-2,878	-2,404	-2,039	-1,652	-3,029	-1,643
Share Based Compensation	-208.3%	-237	219	326	403	129	158	275	81.00	-756	579	756	1,140	398	1,034	1,147	596	-803	374	1,843	2,700	-1,725
Cashflow From Investing	100.8%	22*	-2.74	-18.58	39,929	-30,005	-	-	-	-	-2.94	-	-	-32.70	-1.19	-10*	-2.59	-7.26	-	-2.06	-1.95	7*
Cashflow From Financing	-	-	-	-	-	-	-	-	-	39.00	250	390	20,100	359	5,127	1,201	419	3,331	3,175	180	3,929	1,515

MNOV Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 1,000,000
Operating expenses:
Research, development and patents	5,657,895	$ 9,143,792
General and administrative	5,242,370	5,484,857
Total operating expenses	10,900,265	14,628,649
Operating loss	(9,900,265)	(14,628,649)
Interest income	1,834,665	809,673
Other expense, net	(502,869)	(247,285)
Loss before income taxes	(8,568,469)	(14,066,261)
Income tax expense	(3,047)	(2,822)
Net loss	$ (8,571,516)	$ (14,069,083)
Basic net loss per common share	$ (0.17)	$ (0.29)
Diluted net loss per common share	$ (0.17)	$ (0.29)
Shares used to compute basic net loss per common share	49,046,246	49,045,342
Shares used to compute diluted net loss per common share	49,046,246	49,045,342
Net loss	$ (8,571,516)	$ (14,069,083)
Other comprehensive loss, net of tax:
Foreign currency translation adjustments	(2,805)	(16,408)
Comprehensive loss	$ (8,574,321)	$ (14,085,491)

MNOV Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 50,999,442	$ 18,505,493
Prepaid expenses and other current assets	174,938	499,403
Investments		39,982,213
Total current assets	51,174,380	58,987,109
Goodwill	9,600,240	9,600,240
In-process research and development	4,800,000	4,800,000
Property and equipment, net	45,800	45,269
Right-of-use asset	575,406	629,495
Other non-current assets	74,151	92,792
Total assets	66,269,977	74,154,905
Current liabilities:
Accounts payable	1,003,937	424,646
Accrued liabilities and other current liabilities	2,059,238	2,605,308
Operating lease liability	215,926	157,505
Total current liabilities	3,279,101	3,187,459
Deferred tax liability	201,792	201,792
Other non-current liabilities	410,660	523,619
Total liabilities	3,891,553	3,912,870
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2023 and December 31, 2022; 49,046,246 and 49,046,246 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	49,046	49,046
Additional paid-in capital	478,149,161	477,438,451
Accumulated other comprehensive loss	(118,090)	(115,285)
Accumulated deficit	(415,701,693)	(407,130,177)
Total stockholders’ equity	62,378,424	70,242,035
Total liabilities and stockholders’ equity	$ 66,269,977	$ 74,154,905

About MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

CEO	Dr. Yuichi Iwaki M.D., Ph.D.
WEBSITE	medicinova.com
INDUSTRY	Biotechnology
EMPLOYEES	13

MediciNova Inc Frequently Asked Questions

What is the ticker symbol for MediciNova Inc? What does MNOV stand for in stocks?

MNOV is the stock ticker symbol of MediciNova Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MediciNova Inc (MNOV)?

As of Fri Apr 26 2024, market cap of MediciNova Inc is 64.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MNOV stock?

You can check MNOV's fair value in chart for subscribers.

What is the fair value of MNOV stock?

You can check MNOV's fair value in chart for subscribers. The fair value of MediciNova Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MediciNova Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MNOV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MediciNova Inc a good stock to buy?

The fair value guage provides a quick view whether MNOV is over valued or under valued. Whether MediciNova Inc is cheap or expensive depends on the assumptions which impact MediciNova Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNOV.

What is MediciNova Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, MNOV's PE ratio (Price to Earnings) is -7.5 and Price to Sales (PS) ratio is 35.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MNOV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MediciNova Inc's stock?

In the past 10 years, MediciNova Inc has provided -0.034 (multiply by 100 for percentage) rate of return.